Areas of Interest & Competitive Research Grants - Bristol Myers Squibb

Areas of Interest (AOI)

We are currently accepting concepts for the following therapeutic areas. BMS periodically opens RFP Cycles across different therapeutic areas and the pre-concept submission periods will be posted below when available. We strongly encourage all applicants to begin the online application process early to allow adequate time for completion. For a submission to qualify for review, all information including any required uploads must be submitted through the application form prior to the specified end dates for the RFP Cycle.

Therapeutic Area and / or Compound AOIs Posted on BMS.com Pre-Concept Submission Period
Start Date End date
Immunology – TYK2 (deucravacitinib) 22-Aug-22 19-Sep-22 28-Oct-22
Immunology – Abatacept (Orencia) 19-Sep-22 31-Oct-22 01-Dec-22

Orencia ISR Areas of Interest – RFP 2022-2023

 

Rheumatoid Arthritis:

  • Therapeutic risk benefit profile of abatacept:​
    • Early intervention vs progressing to Rheumatoid Arthritis (RA); Characteristics of abatacept early responders, early remitters, sustained remitters and non-responders; Differential biology of ACPA+ and ACPA- abatacept responders​
  • At-risk RA, pre-RA, arthralgia, early RA:​
    • Patient subsets definition and characterization; Specific clinical endpoints and PROs; Criteria for early interception and intervention​
  • Combinational therapies: ​
    • Safety; Patient subsets; Pathways​
  • Disease pathophysiology: ​
    • Cell free DNA; Role of TLR7/8; Role of p38/MK2; Role of Type 1 interferon; Role of PAD4; Role of Tregs​

Ankylosing Spondylitis (AS):

  • Disease pathophysiology: Mechanism and biomarkers of anti-TNF resistance/response in AS; Role of autoantibodies; Role of TLR7/8; Role of p38/MK2; Role of BTK​
  • Specific clinical endpoints and PROs​

Systemic Sclerosis:​​

  • Disease pathophysiology: Role of autoantibodies; Role of TLR7/8; Role of p38/MK2; Role of BTK​
  • Specific clinical endpoints and PROs​

Other rheumatologic diseases with high unmet medical needs (indication in submission will be "Immunoscience NOS" (not other specified)):

  • Disease pathophysiology: Role of autoantibodies; Role of TLR7/8; Role of p38/MK2; Role of BTK​
  • Specific clinical endpoints and PROs​

Out of Scope:

  • Myositis​
  • Vasculitis​
  • Psoriatic Arthritis​
  • Lupus​
  • Sjögren's syndrome​
  • Common Variable Immunodeficiency​
  • Graft versus Host Disease​
  • Type 1 Diabetes​
  • COVID-19 vaccination​
  • COVID-19 infection​

Please note that during an open RFP submission window, clicking on a link to submit your research idea will take you to the FastTrack Investigator Portal and you will receive a message that you are leaving BMS.com. This is part of the normal process.

  • If you are a potential investigator who is interested in seeking support to conduct independent research involving  Nivolumab  in Japan, Taiwan, or Korea, click here
  • If you are a potential investigator who is interested in seeking support for independent research using Apixaban, click here.
  • If you are a potential investigator who is interested in seeking support for non-clinical research using a BMS product, click here
  • If you are a potential investigator who is interested in seeking support for independent research using one of our early pipeline assets, click here

Please click on the product name to see the Full U.S. Prescribing Information for ELIQUIS®, EMPLICITI, NULOJIX®, OPDIVO®, ORENCIA®, SPRYCEL®, YERVOY®, including Boxed WARNINGS for ELIQUIS®, NULOJIX®, and Boxed WARNING for YERVOY® regarding immune-mediated adverse reactions.


Begin a New Application